What Medications Are Used to Treat Inflammation?

Inflammation is the body’s natural immune response to injury, infection, or irritants—and while acute inflammation is protective and self-limiting, chronic inflammation underlies numerous serious conditions, including rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, and type 2 diabetes. Pharmacologic management of inflammation depends on the underlying cause, severity, duration, and affected organ systems.

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and celecoxib, are first-line agents for mild-to-moderate inflammatory pain and swelling. They work by inhibiting cyclooxygenase (COX) enzymes—primarily COX-1 and COX-2—which reduces prostaglandin synthesis and subsequent vasodilation, edema, and nociceptor sensitization. Selective COX-2 inhibitors offer improved gastrointestinal safety but carry increased cardiovascular risk with long-term use.

For moderate-to-severe systemic inflammation—particularly in autoimmune or allergic contexts—corticosteroids like prednisone, methylprednisolone, or dexamethasone are highly effective. These agents suppress multiple inflammatory pathways, including nuclear factor kappa B (NF-κB) signaling and cytokine production (e.g., IL-1, IL-6, TNF-α). However, their use requires careful risk-benefit assessment due to well-documented adverse effects, including hyperglycemia, osteoporosis, adrenal suppression, and increased infection susceptibility.

In chronic immune-mediated diseases, disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers play a pivotal role. Conventional synthetic DMARDs—including methotrexate, sulfasalazine, and leflunomide—modulate adaptive immunity over weeks to months. Biologics, such as tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab), interleukin antagonists (ustekinumab, secukinumab), and B-cell–depleting agents (rituximab), target specific inflammatory mediators with high precision. JAK inhibitors (e.g., tofacitinib, upadacitinib) represent a newer class of small-molecule immunomodulators that interrupt intracellular cytokine signaling.

Emerging therapeutic strategies include specialized pro-resolving mediators (SPMs)—such as resolvins and protectins—derived from omega-3 fatty acids, which actively promote resolution of inflammation rather than merely suppressing it. While still largely investigational in clinical practice, SPMs reflect a paradigm shift toward resolution pharmacology.

Clinical decision-making must always integrate diagnosis, comorbidities, drug interactions, and patient-specific factors—including age, renal/hepatic function, and pregnancy status. Treatment should be individualized, monitored regularly, and de-escalated when feasible to minimize long-term toxicity while maintaining disease control.